Defence Therapeutics Number Of Employees vs. Current Valuation
| DTCFF Stock | USD 0.41 0.00 0.00% |
For Defence Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Defence Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Defence Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Defence Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Defence Therapeutics over time as well as its relative position and ranking within its peers.
Defence |
Defence Therapeutics Current Valuation vs. Number Of Employees Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Defence Therapeutics's current stock value. Our valuation model uses many indicators to compare Defence Therapeutics value to that of its competitors to determine the firm's financial worth. Defence Therapeutics is one of the top stocks in number of employees category among its peers. It also is rated as one of the top companies in current valuation category among its peers reporting about 15,080,344 of Current Valuation per Number Of Employees. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Defence Therapeutics' earnings, one of the primary drivers of an investment's value.Defence Number Of Employees vs. Competition
Defence Therapeutics is one of the top stocks in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 199. Defence Therapeutics holds roughly 4.0 in number of employees claiming about 2.01% of stocks in Biotechnology industry.
Defence Current Valuation vs. Number Of Employees
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Defence Therapeutics |
| = | 4 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Defence Therapeutics |
| = | 60.32 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Defence Current Valuation vs Competition
Defence Therapeutics is rated as one of the top companies in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 187.35 Million. Defence Therapeutics totals roughly 60.32 Million in current valuation claiming about 32% of stocks in Biotechnology industry.
Defence Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Defence Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Defence Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Defence Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Defence Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar therapeutic drugs for cancer and infectious diseases. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada. Defence Therapeutics is traded on OTC Exchange in the United States.
Defence Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Defence Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Defence Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Defence Therapeutics' important profitability drivers and their relationship over time.
Use Defence Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Defence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Defence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Defence Therapeutics Pair Trading
Defence Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Defence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Defence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Defence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Defence Therapeutics to buy it.
The correlation of Defence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Defence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Defence Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Defence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Defence Therapeutics position
In addition to having Defence Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Dividend Beast Thematic Idea Now
Dividend Beast
An experimental equal-weighted theme of equities with high dividend yield and solid fundamentals based on Macroaxis rating system. The Dividend Beast theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Dividend Beast Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Defence OTC Stock
To fully project Defence Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Defence Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Defence Therapeutics' income statement, its balance sheet, and the statement of cash flows.